Home
    Disclaimer
    4-AcO-MET molecular structure

    4-AcO-MET Stats & Data

    Metacetin 4-acetoxy-met O-acetylmetocin 4acomet
    NPS DataHub
    MW260.34
    FormulaC15H20N2O2
    CAS1445751-40-5
    IUPAC3-(2-Ethyl(methyl)aminoethyl)-1''H''-indol-4-yl acetate
    SMILESCCN(C)CCc1cnc2cccc(OC(C)=O)c12
    InChIKeyOMDKHOOGGJRLLX-UHFFFAOYSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic

    History & Culture

    4-AcO-MET, also known as metacetin, is a novel synthetic tryptamine that emerged primarily through the online research chemical market. As an acetate ester of 4-HO-MET and a structural homologue of 4-AcO-DMT, it represents one of many acetylated tryptamine derivatives that have been synthesized and distributed in recent decades. The compound has very little documented history of human use compared to more established psychedelics. Unlike substances such as psilocybin or LSD, which have decades of clinical research and cultural significance, 4-AcO-MET remains relatively obscure with minimal data regarding its pharmacological properties, metabolism, or toxicity profile. Its availability has been primarily limited to online research chemical vendors, where it is marketed alongside other novel tryptamine analogues.

    Subjective Effect Notes

    cognitive: The cognitive effects of 4-AcO-MET are described by many as somewhat relaxing, yet fast-paced in style with similarities to psychedelics such as LSD or 2C-B which tend to be cognitively energetic and stimulating.

    Effect Profile

    Curated + 36 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10107.5
    Headspace Depth×3
    10102.6
    Auditory Effects×1
    10102.6
    Body Load / Somatic Effects×1
    10103.4
    Catalog Erowid BlueLight

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    80% ●○○
    Psilocybin
    85% ●○○
    Psilocin
    85% ●○○
    Mescaline
    65% ●○○
    DMT
    85% ●○○
    5-MeO-DMT
    85% ●○○
    2C-B
    65% ●○○
    2C-E
    65% ●○○

    Experience Report Analysis

    Erowid BlueLight
    23 Reports
    2013–2025 Date Range
    21 With Age Data
    26 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 36 experience reports (23 Erowid + 13 Bluelight)

    36 Reports
    90 Effects Detected
    48 Positive
    26 Adverse
    16 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 48

    Color Enhancement 69.5% 89%
    Stimulation 60.9% 70%
    Patterning 53.8% 87%
    Empathy 52.2% 70%
    Focus Enhancement 47.8% 70%
    Music Enhancement 47.2% 88%
    Euphoria 47.2% 89%
    Introspection 41.7% 82%
    Entity Imagery 38.5% 86%
    Geometric Imagery 38.5% 88%
    Contentment 38.5% 78%
    Joy 30.8% 89%
    Morphing 30.8% 86%
    Surface Breathing 30.8% 84%
    Warping 23.1% 85%
    Awe 23.1% 83%
    Peace 23.1% 82%
    Tactile Enhancement 19.5% 75%
    Body High 19.4% 90%
    Fractal Imagery 15.4% 88%

    Adverse Effects 26

    Anxiety 38.9% 83%
    Nausea 33.4% 88%
    Thought Disorganization 30.8% 76%
    Muscle Tension 27.8% 75%
    Confusion 25.0% 85%
    Body Load 23.1% 78%
    Chills 23.1% 77%
    Sweating 16.6% 75%
    Thought Acceleration 15.4% 78%
    Fear 15.4% 75%
    Insomnia 15.4% 82%
    Dysphoria 15.4% 78%
    Headache 13.9% 80%
    Increased Heart Rate 13.0% 70%
    Jaw Clenching 13.0% 70%
    Pupil Dilation 11.1% 80%
    Pressure 7.7% 80%
    Memory Suppression 7.7% 80%
    Focus Suppression 7.7% 85%
    Panic 7.7% 75%

    Dosage Distribution

    Dose distribution from experience reports

    Median: 20.0 mg IQR: 15.0–30.0 mg n=13

    Real-World Dose Distribution

    62K Doses

    From 44 individual dose entries

    Oral (n=38)

    Median: 22.5mg 25th: 13.5mg 75th: 31.5mg 90th: 40.0mg
    mg/kg median: 0.289 mg/kg 75th: 0.481

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.284 mg/kg IQR: 0.22–0.508 mg/kg n=13

    Redose Patterns

    Redosing behavior across 13 reports

    15.4% Redosed
    1.3 Avg Doses
    60m Median Interval

    Legal Status

    Country Status Notes
    Germany NpSG (Controlled) Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is illegal but not subject to criminal penalty. Ordering may potentially constitute incitement to place on the market.
    Switzerland Controlled (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
    United Kingdom Class A Controlled as a Class A substance under the Misuse of Drugs Act 1971. Classification stems from being an ester of 4-HO-MET, which itself is controlled under the tryptamine catch-all clause.
    United States Unscheduled Not specifically scheduled under the Controlled Substances Act. However, as a structural analogue of psilocin (a Schedule I substance), sale for human consumption or use for illicit non-medical purposes could potentially be prosecuted under the Federal Analogue Act.
    ← Back to 4-AcO-MET